Compulsory licensing for two AIDS drugs extended by Thailand health authority

16 June 2010

Thailand's National Health Security Office (NHSO)'s board on Monday asked the Public Health Ministry to extend enforcement of compulsory licensing for two drugs for the treatment of AIDS ' efavirenz (Bristol-Myers Squibb's Sustiva) and cocktail formula lopinavir/ritonavir (Abbott Laboratories' Kaletra), reported The Nation online, quoted by the Xinhua news agency.

The decision came after an NHSO board meeting chaired by Public Health Minister Jurin Laksanawisit, at which it was explained that the enforcement of the compulsory licensing of the two AIDS drugs will expire in the next two years.

Mr Jurin said the request to extend the enforcement of the compulsory licensing for these two drugs would be sent to the Department of Disease Control (DDC) for a green light.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK